TABLE 1.

Protective efficacy of Ebola virus NP replicons in C57BL/6 mice^a

Replicon injected	No. of injections	No. of survivors/ total	Days to deathb	No. viremic/totalc	Viremia, GMTe (log10 PFU/ml)
Ebola virus NP	3	15/20	8.0 ± 0.8	5/5	4.1 ± 1.1
	2	8/10	8.5	NDd	ND
Lassa virus N	3	1/20	7.3 ± 0.6	4/4	8.6 ± 0.7
	2	0/10	7.1 ± 0.3	ND	ND

^aMice were injected two or three times at 1-month intervals with the Ebola virus NP replicon or the control Lassa virus N replicon. One month after the final injection, mice were challenged with mouse-adapted Ebola Zaire virus. 

^bThe time to death for mice that did not survive challenge is reported as the mean ± standard deviation for groups with at least three deaths or as the average for the group with two deaths. 

^cNumber of mice with measurable levels of Ebola virus in the sera 5 days post-Ebola virus challenge/total number of mice tested. 

^dND, not determined. 

^eGMT, geometric mean titer of the virus detected in the sera 5 days post-Ebola challenge.